Another company looking to initiate clinical trials with an epigenetic-editor-based treatment for hepatitis is nChroma Bio.

Eli Lilly and Sangamo Therapeutics have entered into a licensing agreement worth over $1.4bn to deliver genomic medicines for ...

Sangamo Therapeutics Inc., a genomic medicine company, has entered into a license agreement with Eli Lilly and Company.

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They ...

Sangamo Therapeutics Inc. is adding a much-needed $18 million up-front payment in a neurology-focused deal with Eli Lilly and Co. that could bring up to an additional $1.4 billion. In return, Lilly ...

Sangamo Therapeutics, Inc.'s $18M Eli Lilly deal boosts CNS genomic medicines. Fabry gene therapy data in 2025 is key for investors. Click for my SGMO stock update.

Struggling US genomic medicines company Sangamo Therapeutics (Nasdaq: SGMO) has been offered a lifeline via a licensing deal with pharma major Eli Lilly (NYSE: LLY), sending its share up 24% to $0.77.

Lilly is the third company to partner with Sangamo on STAC-BBB after Astellas Gene Therapies, which paid $20 million upfront ...

The deal centers on Sangamo’s proprietary STAC-BBB neurotropic adeno-associated virus (AAV) capsid, designed to penetrate the blood-brain barrier and deliver genomic medicines for central nervous ...

Agreement grants Lilly rights to employ Sangamo’s novel proprietary capsid, STAC-BBB, for up to five potential disease targets Sangamo to receive an $18 million upfront license fee and is eligible to ...